635 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: Improvement in body surface area involvement in the phase 3 POETYK PSO-3 trial

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, Japan, and other countries for the treatment of adults with moderate-to-severe plaque psoriasis based on the results of two global phase 3 trials, POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751). Phase 3 POETYK PSO-3 (NCT04167462) examined deucravacitinib in patients from mainland China, Taiwan, and South Korea. The current analysis evaluated the efficacy of deucravacitinib (n=146) vs placebo (n=74) on body surface area (BSA) involvement and a convenient measure of overall severity, BSA by static Physician’s Global Assessment (BSA×sPGA), in PSO-3 at Weeks 16 and 52. Mean baseline scores were similar for patients randomized to deucravacitinib (BSA, 34.1%; BSA×sPGA, 110.3) and placebo (BSA, 33.4%; BSA×sPGA, 109.1). BSA involvement at Week 16 decreased by 68.2% and BSA×sPGA by 78.1% in deucravacitinib-treated patients vs a 12.9% and 8.3% increase, respectively, in placebo patients. At Week 16, 76% of patients treated with deucravacitinib achieved a ≥75% improvement from baseline in BSA×sPGA vs 10.8% with placebo. Improvements in all measures were maintained at Week 52 for patients continuously treated with deucravacitinib; comparable results were observed in placebo patients who crossed over to deucravacitinib at Week 16. These results demonstrate that deucravacitinib treatment was associated with marked improvements in BSA and BSA×sPGA by Week 16 that were sustained through 52 weeks in Asian patients with moderate to severe plaque psoriasis.